Arvinas Target of Unusually High Options Trading (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN) saw some unusual options trading on Wednesday. Investors acquired 5,428 call options on the company. This represents an increase of 155% compared to the typical volume of 2,130 call options.

Arvinas Trading Up 5.9 %

ARVN opened at $17.50 on Thursday. The stock has a market capitalization of $1.20 billion, a P/E ratio of -6.32 and a beta of 1.95. Arvinas has a 12 month low of $15.53 and a 12 month high of $49.76. The firm’s fifty day simple moving average is $18.28 and its 200 day simple moving average is $22.53.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period last year, the business earned ($2.53) EPS. On average, equities research analysts predict that Arvinas will post -3.81 EPS for the current fiscal year.

Insider Activity

In other Arvinas news, insider Ian Taylor sold 9,020 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the transaction, the insider now owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91. This represents a 5.36 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO John G. Houston sold 31,338 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the transaction, the chief executive officer now owns 1,157,480 shares in the company, valued at $19,353,065.60. The trade was a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,572 shares of company stock worth $695,030. 5.23% of the stock is owned by corporate insiders.

Institutional Trading of Arvinas

Hedge funds and other institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. acquired a new stake in Arvinas in the 4th quarter valued at $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Arvinas by 0.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 433,531 shares of the company’s stock valued at $8,311,000 after acquiring an additional 3,047 shares in the last quarter. Voloridge Investment Management LLC acquired a new stake in shares of Arvinas in the fourth quarter valued at about $749,000. Woodline Partners LP raised its holdings in Arvinas by 39.2% during the fourth quarter. Woodline Partners LP now owns 692,733 shares of the company’s stock worth $13,280,000 after acquiring an additional 194,996 shares in the last quarter. Finally, Twinbeech Capital LP acquired a new position in Arvinas during the fourth quarter valued at approximately $3,146,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Barclays dropped their price target on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Oppenheimer upped their target price on shares of Arvinas from $40.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Wedbush reaffirmed an “outperform” rating and set a $57.00 price objective on shares of Arvinas in a research note on Tuesday, February 11th. BMO Capital Markets reissued an “outperform” rating and issued a $82.00 target price (down previously from $88.00) on shares of Arvinas in a research note on Wednesday, February 12th. Finally, Stephens began coverage on Arvinas in a research report on Monday, November 18th. They set an “overweight” rating and a $55.00 target price for the company. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $60.00.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.